DIA: Driving Insights to Action
Science:Life Sciences
In March 2019, the Health Ministry of India released new guidelines for clinical research. What is the state of pre-market and post-market safety for patients and drugs in India, six months after these new guidelines were announced? Dr. Srikanth Krishnamurthy, a consulting pulmonologist at Sri Bala Medical Centre and Hospital, discusses the pre-market clinical research safety perspective; and Dr. J. Vijay Venkatraman, Managing Director and CEO at Oviya MedSafe, contributes the perspective of post-market drug safety in India.
Risk Inherent in Benefits of Drug/Device Products?
EU Business and Data Needs Converge Through Telematics
RIM Accelerating Efficiencies in Regulatory Pathways
Translating Clinical Trials into Clinical Benefit
More Tools & Data Sources: More Insights for RBM?
Landmark AMA to Rely on Regulatory Reliance
Healthy Population Key to Economic Success
Defining Rational Medicine and Research at DIA Japan 2019
How Do You Put Your Disease on the Agenda?
Participatory Medicine Changing Information Exchange
Real World Data Expanding into Label Expansion
Educating Persons Critical in Personalized Medicine
FDA Payer Communication Guidance Steps Toward Sustainability
Genetic Engineering Transforming Research Ethics
Only Big Trust Propels Big Data into Big Discoveries
Empowering Today’s Patients to Help Tomorrow’s
Imaging Data Plus AI “One of the Best Combinations”
Clinical Trial Diversity Begins (and Ends) with Patients First
Califf: Digitization Will Return Humanity to Medicine
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology